At the time of writing, Kyverna Therapeutics Inc [KYTX] stock is trading at $2.58, up 13.66%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The KYTX shares have gain 24.64% over the last week, with a monthly amount glided 22.86%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kyverna Therapeutics Inc [NASDAQ: KYTX] stock has seen the most recent analyst activity on May 27, 2025, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $5 for it. Previously, UBS started tracking the stock with Buy rating on October 10, 2024, and set its price target to $13. On October 09, 2024, Rodman & Renshaw initiated with a Buy rating and assigned a price target of $16 on the stock. H.C. Wainwright started tracking the stock assigning a Neutral rating and suggested a price target of $8 on July 03, 2024. Wells Fargo initiated its recommendation with a Overweight and recommended $44 as its price target on March 04, 2024. Morgan Stanley started tracking with a Overweight rating for this stock on March 04, 2024, and assigned it a price target of $40. In a note dated March 04, 2024, Leerink Partners initiated an Outperform rating and provided a target price of $48 on this stock.
For the past year, the stock price of Kyverna Therapeutics Inc fluctuated between $1.78 and $16.64. Kyverna Therapeutics Inc [NASDAQ: KYTX] shares were valued at $2.58 at the most recent close of the market.
Analyzing the KYTX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.56, Equity is -0.52 and Total Capital is -0.71. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.41 points at the first support level, and at 2.25 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.78, and for the 2nd resistance point, it is at 2.99.
Ratios To Look Out For
It is important to note that Kyverna Therapeutics Inc [NASDAQ:KYTX] has a current ratio of 7.44. Further, the Quick Ratio stands at 7.44, while the Cash Ratio is 1.71.
